Transaction DateRecipientSharesTypePriceValue
8th September 2020Des Produits Nestle S.A. Societe4,305,541Other acquisition or disposition$4.42$19,030,491.22
31st August 2020David R Epstein2,752Open or private purchase$4.46$12,273.92
31st August 2020David R Epstein1,000Open or private purchase$4.47$4,470.00
31st August 2020David R Epstein1,000Open or private purchase$4.58$4,580.00
31st August 2020David R Epstein1,000Open or private purchase$4.48$4,480.00
28th August 2020David R Epstein3,248Open or private purchase$4.40$14,291.20
28th August 2020David R Epstein1,000Open or private purchase$4.34$4,340.00
17th August 2020Ventures Fund Iv General Partner Llc Flagship2,053,049Other acquisition or disposition$0.00
17th August 2020Ventures Fund Iv General Partner Llc Flagship7,550,810Other acquisition or disposition$0.00
17th August 2020Ventures Fund Iv General Partner Llc Flagship1,449,190Other acquisition or disposition$0.00
Axcella Health
Axcella Health logo

Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 10/10.


Axcella Health, Inc. engages in the research and development of novel multifactorial interventions to support health. The company was founded by Noubar B. Afeyan, Geoffrey von Maltzahn, and David A. Berry on August 27, 2008.


Ticker: AXLA
Sector: Health Technology
Industry: Biotechnology
SEC Central Index Key (CIK): 1633070
Employees: 64
Exchange: NASDAQ
Auditor Opinion:

Disclosure Language changes
Red Flags
Fundamentals
Assets, Current: $124 M (32%)
Property, Plant and Equipment, Net: $357 Th (0%)
Assets: $125 M (31%)
Long-term Debt, Current Maturities: $5 M (0%)
Accounts Payable, Current: $2 M (-18%)
Accrued Liabilities, Current: $4 M (0%)
Liabilities, Current: $11 M (31%)
Other Liabilities, Noncurrent: $945 Th (7%)
Liabilities: $32 M (-7%)
Common Stock, Value, Issued: $37 Th (54%)
Common Stock, Shares, Issued: $37 M (55%)
Retained Earnings (Accumulated Deficit): $245 M (0%)
Treasury Stock, Shares: $4 M (0%)
Stockholders' Equity (Parent): $93 M (0%)
Liabilities and Equity: $125 M (31%)
Research and Development: $9 M (-54%)
General and Administrative Expenses: $5 M (-47%)
Operating Income/Loss: $13 M (-52%)
Other Income, net: $708 Th (-43%)